美股異動|瑞銀盤前升超1.5% Q2業績超預期 財管新流入資金達270億美元
瑞銀(UBS.US)美股盤前升超1.5%,報29.7美元。消息面上,瑞銀公佈第二季度業績,營收為119億美元,同比增長24.7%,高於市場預期的114.7億美元;攤薄後每股收益為0.34美元,亦超過市場預期的0.12美元。期內關鍵的財富管理業務獲強勁流入,當期淨新資產達270億美元。在完成對瑞士信貸的收購一年後,瑞銀有望達到合併前的盈利水平,並計劃到2026年回購約20億美元的股票。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.